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Background/aim: Epidemiological evidence suggests that diabetes poses a high risk for many chronic diseases, especially cardiovascular
diseases, and cancer by stimulating many inflammatory and immunological pathogenic mediators and affecting natural killer (NK)-cell
activity. In this study, the effects of melatonin and resveratrol on IL-6, TNF-alpha, oxidant/antioxidant capacity, NK-cell activity, and
mid-regional proadrenomedullin (MR-proADM) levels of diabetic rats were investigated.
Materials and methods: In the study, 28 Sprague Dawley rats were randomly divided into the control group (group I) and 3 streptozotocininduced diabetes mellitus (DM) groups (group II, III, and IV), each group consisting of 7 rats. Five mg/kg/day melatonin to group III
and 5 mg/kg/day resveratrol (intraperitoneal) to group IV was given. At the end of 3 weeks, NK-cell activity, total antioxidant/oxidant
capacity, MR-proADM, IL-6, and TNF-alpha levels were measured in intracardiac blood taken under anesthesia.
Results: NK-cell activity of group II was found lower than group I, group III, and group IV (7.4 ± 2.0 vs. 22.5 ± 11.9, 30.6 ± 22.5 and 20.4
± 9.1 pg/mL; p = 0.0018, respectively). The difference was more prominent in diabetic rats receiving melatonin (p < 0.01). TNF-alpha
levels of group II were higher than the group I (p < 0.05). The MR-proADM levels of group II were found to be lower than the group I
and group III (6.4 ± 3.6 vs. 14.4 ± 3.2 and 14.0 ± 4.2 ng/L; p < 0.05, respectively). In addition, NK-cell activity was moderately correlated
with MR-proADM (r = 0.5618, p = 0.0019).
Conclusion: Resveratrol and, more effectively, melatonin modulate by reversing the adverse effects of diabetes on NK-cell activity,
which has a protective function in inflammatory and immunological processes. In this modulation, melatonin also acts through
adrenomedullin.
Key words: Diabetes mellitus, melatonin, resveratrol, natural killer cell activity, mid-regional proadrenomedullin

1. Introduction
Diabetes mellitus (DM), whose incidence is constantly
increasing globally, is a chronic and serious metabolic
disease causing the deadliest health problems worldwide.
Epidemiological evidence suggests that DM poses a
high risk for many types of diseases, including cancer,
primarily cardiovascular. Inflammatory, immunological,
and endocrinological factors that are effective in this
deterioration transforming process of DM appear to be
associated with the incidence or mortality of the diseases
[1,2]. Every day, the structure of thousands of cells in
our body deteriorates due to various microorganisms,
harmful substances, rays, and chronic diseases such
as DM. Natural killer (NK) cells, which are a kind of
lymphocyte cell and have a wide variety of biological

activities, can correct inflammation in tissues invaded by
pathogens. They can recognize disrupted cells that tend
to differentiate into cancer from the changed antigenic
structure and destroy them. In addition, they can also
eliminate immune dysfunction. For this reason, NK-cell
count is very important in the body’s fight against diseases.
However, recently it has been realized that NK-cell activity
is more important than NK-cell count because it has been
observed that although the NK-cell count is high, they
cannot fulfill their protective functions against cancer
[3,4]. In addition to many chronic adverse effects of DM, it
was found to impair glucose transporter (GLUT) protein
expression and decrease NK-cell activity associated with
it. This suggests that diabetes has an important role in the
pathogenesis of many chronic diseases. In addition, today,
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abnormalities in oxidant and antioxidant systems, growth
factors, adrenomedullin (ADM), inflammatory cytokines
(interleukin-1beta (IL-1β)), various interleukins (IL-6,
IL-15, IL-17, and IL-18), tumor necrosis factor-alpha
(TNF-α), and chemokines are considered to contribute to
the pathogenesis of DM-related disorders, inflammatory
diseases, and cancers by activating various transcription
factors [4–7]. Therefore, the determination of direct or
indirect relationships with NK-cell activity of agents such
as melatonin and resveratrol [8,9], which are known to be
associated with the above biological mediators, may lead
to finding preventive treatment options that can prevent
or reduce the degradation of normal cells.
In this study, a completely insulin-free in vivo diabetic
environment was created using streptozotocin to induce
the adverse effects on NK-cell activity by disrupting the
expression of insulin-dependent GLUTs in rats’ NK-cells.
Subsequently, the effects of resveratrol and melatonin on
NK-cell activity were investigated. In addition, the changes
in total antioxidant/oxidant status, mid-regional proADM
(MR-proADM is a more stable part of proADM than
ADM and is more suitable for measurement), IL-6 and
TNF-α levels, which we think may be associated with NKcell activity, were examined.
2. Material and methods
2.1. Experimental protocol
Approval for the study was obtained from the University
of Health Sciences Animal Experiments Local Ethics
Committee (protocol number: 46418926-605.02, 201908/02). The research was planned as an experimental
study with analytical prospective study type. This study
was carried out between May and June 2020. A total
of 28 Sprague Dawley, male, adult rats, 16–20 weeks
old and weighing 250–350 g, were used. Standard care
and nutrition were given to the rats. Rats were kept in
laboratory conditions at an ambient temperature of 20–22
°C and in a circadian rhythm of 12 h night and 12 h day.
Rats were randomized into four groups (group I, II, III
and IV) containing 7 rats in each. All rats were fasted for
12 h before the intracardiac blood collection. Then their
body weights were recorded. A single dose of 60 mg/kg
streptozotocin dissolved in (0.1 M) sodium-citrate buffer
(pH 4.5) was administered intraperitoneally (IP) to groups
II, III, and IV for the development of DM. Then, 48 h after
the administration of streptozotocin, glucose levels were
measured with a glucometer from a drop of blood taken
from the dorsal veins of the hind feet of rats. Rats with
blood glucose levels above 200 mg/dL were considered as
diabetic [10].
2.2. Rat groups
Group I (control group): To eliminate the effects of the
sodium-citrate buffer, this non-diabetic group was given

the same amount of IP sodium-citrate buffer as used to
dissolve streptozotocin. In addition, 25% ethanol-saline
solution used as the solvent of melatonin and resveratrol
was given as IP in the same amount as the other groups
every day between 18:00 and 19:00 for 3 weeks. The aim
here was to eliminate the possible effects of ethanol-saline
solution in which melatonin and resveratrol are dissolved.
Group II (DM group): As was done in group I, 25%
ethanol-saline solution was given to this diabetic control
group as IP every day between 18:00 and 19:00 for 3 weeks.
Group III (DM + Melatonin group): In this diabetic
group, melatonin prepared by dissolving in 25% ethanolsaline solution was administered at a dose of 5 mg/kg/
day for 3 weeks between 18:00 and 19:00 [11]. The rats
were taken to a dark environment after the injection [12].
To better observe the melatonin-related effects, the rats
in groups I, II and IV, which were not given melatonin,
were also taken to the dark-light period with a similar
application.
Group IV (DM + Resveratrol group): In this diabetic
group, resveratrol prepared by dissolving in 25% ethanolsaline solution was injected IP at a dose of 5 mg/kg/day for
3 weeks between 18:00 and 19:00 [13].
Streptozotocin (≥ 75% α-anomer basis, ≥ 98% HPLC),
melatonin (≥ 98% TLC) and resveratrol (≥ 99% HPLC)
were obtained from Sigma-Aldrich (Saint Louis, USA).
2.3. Surgical procedures
The same general anesthesia was applied to all rats.
Anesthesia was provided by IP administration of a
combination of ketamine 100 mg/kg and xylazine 10 mg/
kg. Anesthesia was applied 30 min before the surgical
procedure. When necessary, 1/3 of the initial dose was
repeated as a maintenance dose. All rats were sacrificed
by cervical dislocation after intracardiac blood collection
at the end of the third week under anesthesia. Some of
the blood taken from the rats was put into NK activity
tubes specially prepared for the NK-cell activity test. NK
activity tubes were removed from the refrigerator just
before blood collection and the procedure was performed
within 5 min. The plasma obtained from the blood in these
NK activity tubes was stored at –80 oC until measurement
day (maximum 3 months). Blood from rats to serum
tubes was centrifuged at 3500 RPM for 10 min. Sera
separated by centrifugation were stored at –80 oC until
the measurement day. Total antioxidant status (TAS), total
oxidant status (TOS), MR-proADM, IL-6, and TNF-α
levels were measured in these sera.
2.4. Analysis of biochemical parameters
NK-Cell activity levels: NK-cell activity test enzymelinked immunosorbent assay (ELISA) kit (ATGen,
Seongnam-si, South Korea) was used for NK-cell activity
measurement. The sensitivity of the test kit was 40 pg/ml
and the measuring range was 40–2000 pg/mL.
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Special NK activity tubes (ATGen, Seongnam-si,
South Korea) used for NK-cell activity tests are vacuum
blood collection tubes containing Promoca and heparin
as anticoagulant. Immediately after blood was drawn into
NK activity tubes, the contents of the tube were gently
inverted and mixed. 15 min after blood collection, NK
activity tubes were transferred to the incubator. Attention
was paid to not cool the blood collected in NK activity
tubes before incubation. NK activity tubes containing
blood were incubated at 37 oC for 20–24 h to obtain the
appropriate response from NK-cells in the blood. At
the end of the incubation, the clear or yellowish clear
plasma which remained on top was carefully transferred
into microcentrifuge tubes. This plasma was stored in a
refrigerator at +2 °C to 8 °C for 1 day or at –20 °C for 3
months until the study was performed. Plasma samples
frozen before the study should be thawed at room
temperature and then centrifuged at 11,500 g for 1 min at
room temperature.
NK activity tubes contained a stimulating stabilized
immunomodulatory cytokine called Promoca. During
the incubation process, cytokine-stimulated NK-cells
were induced to secrete interferon-gamma (IFN-) into
plasma. IFN-levels were measured as absorbance at
450 nm in ELISA device (BioTek Epoch 2 Microplate
Spectrophotometer and ELx50 Microplate Strip Washer,
USA).
Rat IL-6 and TNF-α levels: Serum IL-6 and TNF-α
levels of the blood samples were analyzed using the
double antibody sandwich-ELISA method (Elabscience
Biotechnology Co. Ltd, Wuhan, China). The sensitivity of
the IL-6 assay is 7.5 pg/mL, the measuring range is 12.5–
800 pg/mL, and the CV is < 10%. The sensitivity of the
TNF-α assay is 46.9 pg/mL, the measuring range is 78.1–
5000 pg/mL, and the CV is < 10%.
Rat MR-proADM levels: Rat serum MR-proADM
levels were analyzed using double antibody sandwichELISA method kits (Bioassay Technology Laboratory,
Shanghai, China). The sensitivity of MR-proADM assay
was 0.58 ng/L, measuring range 1–380 ng/L, and intraassay
and interassay CV were < 8% and < 10%, respectively.
Rat total oxidant/antioxidant status: Rat TOS and
TAS levels were analyzed using double antibody sandwichELISA method kits (Bioassay Technology Laboratory,
Shanghai, China). The sensitivity of both TOS and TAS
test kits was specified as 0.013 U/mL, measurement range
0.2–60 U/mL, and intraassay and interassay CVs < 8% and
< 10%.
2.5. Statistical analysis
IBM SPSS Statistics v: 20.0 ( IBM Corp., Chicago, USA)
Software was used for statistical analysis of all data. In
comparison of statistical data with normal distribution
and containing more than two independent groups, oneway ANOVA with Post-Hoc test was used. If the data did
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not have a normal distribution, the Kruskal–Wallis with
Post-Hoc test was used. Pearson correlation analysis was
used for correlational studies of data with parametric
distribution, and Spearman correlation analysis was used
for nonparametric data.
3. Results
3.1. Characteristics of rats used in the experimental study
In the study, there was no statistical difference between the
mean ages and weights of the rats included in group I, II,
III, and IV (age: 17.9 ± 1.3, 18.1 ± 1.2, 17.7 ± 1.7 and 17.9 ±
0.9 weeks, p = 0.9077; 298 ± 20, 294 ± 19, 289 ± 24 and 292
± 24 g, p = 0.7219, respectively) (Table 1).
3.2. Comparisons between groups
When the experimental groups were evaluated, the NK-cell
activity of group II was found to be lower than Group-I (7.4
± 2.0 vs. 22.5 ± 11.9 U/mL, respectively; p < 0.05) (Table 1).
The NK-cell activity was higher in diabetic rats in group
III and group IV compared to group II (30.6 ± 22.5 and
20.4 ± 9.1 vs. 7.4 ± 2.0 U/mL; p < 0.05, respectively). The
difference was more prominent in diabetic rats receiving
melatonin (p < 0.01) (Figure 1A). The NK-cell activity of
diabetic rats in group III and group IV was not statistically
different from group I (p > 0.05). Similarly, there was no
difference between NK-cell activities of diabetic rats in
group III and group IV (30.6 ± 22.5 vs. 20.4 ± 9.1 U/mL; p
> 0.05, respectively).
When the experimental groups were evaluated in terms
of IL-6, levels in group II were much higher compared to
the group I (78.6 ± 62.0 vs. 25.2 ± 9.3 pg/mL; p < 0.05,
respectively) (Table 1). Although IL-6 levels of diabetic rats
in group III and group IV were lower compared to group II,
the difference was not statistically significant (38.5 ± 27.6
and 56.3 ± 45.6 vs. 78.6 ± 62.0 pg/mL; p > 0.05, respectively)
(Figure 1B). In addition, it was noteworthy that there was
no difference among IL-6 levels of rats in group I, III, and
IV (25.2 ± 9.3 vs. 38.5 ± 27.6 and 56.3 ± 45.6 pg/mL; p >
0.05, respectively).
The MR-proADM levels in group II were lower
compared to group I and group III (6.4 ± 3.6 vs. 14.4 ± 3.2
and 14.0 ± 4.2 ng/L; p < 0.05, respectively), while the MRproADM levels of group IV were not different (6.4 ± 3 vs.
11.1 ± 4.3 ng/L; p > 0.05, respectively) (Table 1 and Figure
1C). However, MR-proADM levels of diabetic rats in group
III and group IV were not statistically different compared
to group I (14.0 ± 4.2 and 11.1 ± 4.3 vs. 14.4 ± 3.2 ng/L;
p > 0.05, respectively). Similarly, there was no difference
between MR-proADM levels of group III and IV diabetic
rats (14.0 ± 4.2.6 vs. 11.1 ± 4.3 ng/L; p > 0.05, respectively).
All groups were not different in terms of TNF-α, TAS,
TOS (p > 0.05) (Table 1) (Figures 2A-C). However, we
think that this situation should be confirmed with a larger
population.
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Table 1. Comparison of the data according to NK-cell activity, IL-6, MR-proADM, TNF-α, total antioxidant status, and total oxidant
status.
Group I

Group II

Group III

Group IV

p

n

7

7

7

7

-

Age, weeks

18.0(16.0–20.0)

18.0(17.0–20.0)

17.0(16.0–20.0)

18.0(17.0–19.0)

0.91a

Weight, g

300(274–332)

292(271–320)

281(268–339)

286(270–342)

0.72a

NK-cell activity, pg/mL*

20.0(12.6–47.5)

7.6(5.1–11.3)

21.3(11.3–62.6)

16.3(11.3–36.2)

p from post-test

<0.05, >0.05, >0.05, <0.01, <0.05, >0.05

IL-6, pg/mL*

22.8(16.8–44.0)

26.1(17.5–82.8)

33.1(17.7–148.6)

p from post-test

<0.05, >0.05, >0.05, >0.05, >0.05, >0.05

MR-proADM, ng/L*

14.3(10.5–20.0)

15.7(5.9–18.1)

8.8(6.7–17.9)

0.01a

p from post-test

<0.05, >0.05, >0.05, <0.05, >0.05, >0.05

TNF-α, pg/mL

63(42–190)

141(67–262)

79(48–80)

120(24–236)

0.33a

TAS, U/mL

3.15(2.44–3.95)

2.68(1.56–3.39)

2.57(0.98–3.98)

2.84(2.57–3.61)

0.75a

TOS, U/mL

1.66(0.74–2.99)

2.18(0.97–4.16)

1.73(0.72–4.11)

2.62(0.71–5.47)

0.43a

59.4(25.3–200.8)
5.6(2.3–13.4)

0.01a
0.04a

Kruskal–Wallis test, * If p value obtained by ANOVA is <0.05, p values of between groups (respectively, groups I-II, groups I- III,
groups I-IV, groups II-III, groups II-IV and groups III-IV) are compared with post-test and nonparametric data are given as median
(min-max). Group I: Control group, Group II: Diabetes Mellitus (DM) group, Group III: DM+ Melatonin, Group IV: DM+Resveratrol
group, g: Gram, NK: Natural killer, IL: Interleukin, MR-proADM: Midregional-proadrenomedullin, TNF-α: Tumor necrosis factoralpha, TAS: Total antioxidant status, TOS: Total oxidant status.
a

3.3. Correlational studies
According to the correlation analysis results, NK-cell
activity showed a positive correlation with MR-proADM
(Spearman rs = 0.562, p = 0.0019) (Table 2), but the
correlation with TAS and TNF-α became statistically
insignificant (Spearman r = 0.208, p = 0.2873, Spearman
r = –0.318; p = 0.0994, respectively) (Figure 3). Also, there
was no significant correlation between NK-cell activity
and IL-6 (Spearman r = –0.1550, p = 0.4311). Moreover,
the significant correlation between IL-6 and TOS was
found to decrease to r = 0.389 (p = 0.0407).
4. Discussion
Diabetes is a multifaceted disorder that occurs in glucose
use and insulin-related metabolic processes. Genetic
predisposition, lifestyle, diet, limited physical activity,
obesity, aging, and immunological disorders can also
trigger DM. All these risk factors can reveal common
pathogenic mediators of diabetes by stimulating the
inflammatory and immunological pathways. Metabolic
models created by diabetes offer an effective area of
investigation in understanding the possible mechanisms
that direct inflammatory and immunological pathways.
In this way, it is possible to prevent or control diabetes
and diabetes-related pathologies through the resulting
responses [2,14].
NK-cells, which make up about 5%–19% of blood

lymphocytes, protect the body against infection, abnormal
inflammatory response, and cancer by activation through
various cell surface receptors. They can secrete cytokines
through the CD56/CD16 receptor and destroy infected,
disrupted, or cancerous target cells with cytotoxic granule
exocytosis and antibody dependent cellular toxicity. They
are also effective in shaping the acquired immune response
[15,16]. In addition, low NK-cell activity is thought to be
associated with type 1 DM pathogenesis [17]. Some agents
such as vitamins, polysaccharides, and lectins obtained
from plant extracts, which have stimulating properties
for NK-cells, are considered as an option for treatment
to benefit from these functions of NK-cells [18]. If these
options can stimulate NK-cell activity at an adequate level,
the development of many complications of diabetes, which
tend to increase especially with aging, will be preventable.
It has been known that peripheral blood lymphocytes
are particularly sensitive to changes in blood glucose
levels. In addition, lymphocytes are more durable than
granulocytes and can be obtained easily [19]. Therefore,
the use of lymphocytes (NK-cells) in the investigation of
the chronic effects of diabetes is very appropriate. In our
study, we used diabetic rats to better observe the changes in
NK-cell activity. Thought to modulate the immune system
associated with NK-cell activity in recent years, resveratrol
is a stilbene compound (phytoalexins) often synthesized
by plants in response to stressful stimuli [20]. It was
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(a)
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a

P
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0.009
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MR -proADM, ng/L
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>0.05
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>0.05
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5
0

Group I

Group II Group III Group IV

(c)
Figure 1. Box plots graph comparing NK-cell activities, IL-6 levels and MR-proADM levels in control group (group I), diabetic group
(group II), DM + melatonin (group III) and DM + resveratrol group (group IV). The NK-cell activities, IL-6 levels, and MR-proADM
levels were compared with the Kruskal-Wallis test (nonparametric ANOVA) due to the number of samples in the groups. A) While
NK-cell activity was lower in the diabetic group compared to the control group, NK-cell activity increased again in the diabetic groups
receiving melatonin and resveratrol. B) IL-6 levels appear to be higher in the diabetic group compared to the control group. However,
the values in the diabetic groups administered melatonin and resveratrol are not different from the control group. C) MR-proADM
levels are lower in the diabetic group compared to the control group. However, there is no difference in the diabetic groups receiving
melatonin and resveratrol compared to the control group. Compared to the diabetic group, rats receiving melatonin had higher MRproADM levels.
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7
0.330

P

Total Oxidant Status, U/mL

400
350

TNF-α, pg/mL
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0

P
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(a)
6
0.746

Total Antioxidant Status, U/mL

P

5
4
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2
1
0
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Group II

Group III
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(c)

Figure 2. Box plots graph comparing control group (group I), diabetic group (group II), DM + melatonin (group III), and DM +
resveratrol groups (group IV) in terms of TNF-α, TAS and TOS levels. There is no difference between the groups in terms of these
parameters.

reported that this compound has an anti-hyperglycemic
effect by stimulating the intracellular transport of glucose
in diabetic animals [21]. In our experimental rat study,
the NK-cell activity was much lower in the diabetic rat
group compared to the control group, while the high level
in diabetic rats receiving resveratrol was consistent with
the above information indicating its efficacy. This finding
is evidence of the effect of resveratrol on NK-cell activity.
The reason for the low NK-cell activity found in diabetic
rats was attributed to the decrease in glucose transport
to NK-cells in the absence of insulin. Hence, NK-activity
will also slow down as it will lack energy in the absence of

insulin [5]. In this current study, the intake of resveratrol
may have been eliminated the negative effect caused by
the lack of insulin so that NK-cell activity was restored.
This hypothesis is in line with the information reported by
Vallianou et al. [21], in 2013, that resveratrol increases the
expression of the glucose transporter GLUT4 by showing
an insulin-like effect. A similar study found that resveratrol
improved insulin resistance and glucose homeostasis in
obese men with Caucasian metabolic syndrome [22].
However, all these results are not sufficient to explain the
precise mechanism of resveratrol in NK-cell activity and
there is still a need for detailed molecular research.
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Table 2. Correlation results of data for all rat groups.
Spearman’s correlation coefficient (rs)

n:28

A:

A:NK-cell activity

1.000

B:IL-6

–0.155

C:MR-proADM

B:

C:

D:

E:

F:

1.000

0.562**

–0.383*

1.000

D:TNF-α

–0.318

0.336

–0.360

1.000

E:TAS

0.208

–0.150

0.061

–0.163

1.000

F:TOS

0.068

0.389*

–0.2266

–0.068

0.054

1.000

* The P value is < 0.05. ** The P value is < 0.01. The p-value of insignificant correlations was not given.
Spearman’s correlation results are evaluated according to the nonparametric data.

Mr-proADM, ng/L

MR -proADM - IL -6

50

IL-6, pg/mL

40
30
20

y = -0.008x + 16.979
Spearman r = -0.155 p =0.431
y = 0.140x + 8.626
Spearman r = 0.562 p=0.002

10
0

0

10

20

30

NK-Cell Activity, pg/mL

40

Figure 3. Correlation plot showing the relationship between NK-cell activity, MRproADM, and IL-6 levels. The graph shows the direct proportional correlation of NK
cell activity with MR-proADM.

In a study by Kimura and Okuda investigating
metastatic lung carcinoma, they found that resveratrol
significantly reduced tumor volume, weight, and lung
metastasis only at high doses (2.5 and 10 mg/kg) without
affecting the number of CD4+ (helper), CD8+ (cytotoxic),
and NK-cells in the spleen [23]. Although this finding
seems to contradict our results, they differ from us because
they did not evaluate NK-cell activity and, they did not
use diabetic subjects. In another study, whose results we
think may be related to NK-cell activity, resveratrol has
been reported to modulate immune function depending
on the dose. The same study also found that low doses of
resveratrol stimulate the immune system, while high doses
suppress the immune system [24]. In this current study,
resveratrol provided a significant increase in NK-cell
activity. This situation showed that the dose (5 mg/kg/day)
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used in rats could be sufficient to stimulate the immune
system.
Insulin resistance, insulin-like growth factors,
hyperglycemia, hyperlipidemia and inflammatory
cytokines were associated with the risk of cancer developing
[25]. It is considered that the most likely mechanism that
could explain the progression to cancer is a decrease in
NK-cell activity and an abnormal inflammatory response
due to an imbalance in insulin. In our study, the fact
that NK-cell activity and MR-proADM, which has antiinflammatory properties, were significantly lower and
IL-6, a proinflammatory cytokine, was higher in diabetic
rats supported this view. In addition, the increase in NKcell activity and MR-proADM in rats receiving melatonin
and resveratrol, despite they are diabetic, unlike IL-6, were
promising results in the transformation of pathological
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processes. Apparently, NK-cell activity in rats was also
effective, possibly by accelerating antiinflammatory
processes or by suppressing proinflammatory cytokines.
In addition, the moderate correlation detected between
NK-cell activity and MD-proADM is an important proof
of this hypothesis.
Melatonin, a neurohormone synthesized by the
pineal gland from tryptophan, is a modulator in immune
cell production and functions, including NK-cells and
lymphocyte subgroups, as well as providing antioxidant
protection by scavenging free radicals. Although the
exact mechanism is unknown, it has been reported that
melatonin administration stimulates the secretion of
cytokines such as IFN-γ, IL-6, IL-2, and TNF-α [26,27]
and is associated with type 1 DM [28]. The determination
in our study that diabetic rats receiving melatonin have
higher NK-cell activity provides useful data to overcome
the above information gap. The likely reason for the
recovery of this NK-cell activity is that the reduced NK-cell
activity due to lack of insulin is substantially recovered via
melatonin. This situation was attributed to the melatonin
receptor-mediated melatonin-insulin antagonist effect, a
member of the G protein coupled receptor (GPCR) family
[29,30].
Previously it was reported that IL-6, especially TNF-α,
may have an important role in the etiology of diabetes
and insulin resistance, and IL-6 levels may increase 2–3
times [31,32]. Contrary to this information, it has been
reported that IL-6, a pleiotropic cytokine, does not cause
insulin resistance and may even be beneficial for diabetes
in some cases [33]. In our study, while the levels of TNF-α
were not different in all groups, only the diabetic rat group
had high IL-6 levels. The possible reason for this elevation
may be the chronic inflammatory effect of diabetes, which
develops due to the absence of insulin and is accompanied
by low NK-cell activity. Moreover, the high IL-6 level in
the serum of the patients as well as the deterioration in
NK-cell function in systemic juvenile idiopathic arthritis,
which is a chronic inflammatory and autoimmune
disorder, supports our view [34]. This finding significantly
overlaps with our results.
Another important result of our study was the
comparison of melatonin and resveratrol in terms of their
effects on NK-cell activity. In this context, there was a
much greater increase in NK-cell activity in diabetic rats
given melatonin compared to resveratrol. The possible
mechanism underlying this has been attributed to
melatonin being a powerful stimulus of the antioxidant
systems and the ability of melatonin receptors to interact
with many different proteins [35,36]. However, the fact
that there was no difference between the groups in terms
of TAS and TOS in our study suggested that approaches
in which more specific components of oxidative damage
studies may be needed. Some researchers reported that

there may be still unknown oxidants/antioxidants and
those different types of oxidants/antioxidants in the same
system can interact with each other, confirming this idea
[37]. Therefore, it does not seem possible to precisely
explain the relationship between the NK-cell activity and
oxidative/antioxidative system, which has highly complex
molecular mechanisms beyond what is known, based on
only TAS and TOS.
Another interesting finding of this study was the
determination of serum MR-proADM levels parallel to NKcell activity. Compared to the control group, both NK-cell
activity and MR-proADM levels were lower in diabetic rats,
while levels in diabetic rats receiving melatonin were close
to the control group. In the literature review we conducted
to explain this interesting relationship, it was understood
that ADM has very complex effects on various organs and
tissues [38]. It increases intracellular Ca++ independent
from cAMP. In this way, endothelial nitric oxide synthase is
activated and vasodilation occurs with nitric oxide release
[39]. Additionally, ADM modulates protein kinase G
activation (nitric oxide/cGMP/protein kinase G signaling
pathway) by increasing the level of guanosine 3′,5′-cyclic
monophosphate (cGMP) via nitric oxide [40]. Besides
its these complex metabolic functions, ADM was found
to be closely related to members of the inflammatory
process [41]. ADM also provides antiinflammatory effect
by suppressing the release of TNF-α and IL-1β through
IL-10, while stimulating proinflammatory cytokine release
such as IL-6 and IL-10 [42]. Administration of ADM to
transgenic mice restored early insulin resistance in adipose
tissue by inhibiting adipocyte major histocompatibility
complex class II (MHC II) antigen presentation and CD4
(+) T cell activation [43]. Therefore, it is understood
that ADM has a regulatory effect on proinflammatory
and antiinflammatory cytokines, members of oxidant/
antioxidant system and mediators related to insulin
resistance. All the above information explains why while
MR-proADM levels were found to be higher in diabetic
rats given melatonin compared to diabetic rats, IL-6 levels
decreased to the levels of the control group. However, this
view needs confirmation.
The results obtained in the study belong to animal
experiments. This experimental study is not fully applicable
to humans. In conclusion, resveratrol and, more effectively,
melatonin modulate by reversing the adverse effects of
diabetes on NK-cell activity, which has a protective function
in inflammatory and immunological processes. In this
modulation, melatonin also acts through adrenomedullin.
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